Pramipexol - 1 A Pharma

Quick links

Choose a section

Quick links to important sections

Advertisements

Pramipexol - 1 A Pharma

Advertisements
Advertisements

Method of action: Antiparkinsonian, Dopaminergic

Advertisements

Overview of Pramipexol - 1 A Pharma

This section establishes the core identity and classification of Pramipexol - 1 A Pharma, focusing solely on its nature, composition, and general purpose as a medicine.

Property Description
Active ingredient Pramipexole
Form Tablet (Immediate- and Prolonged-release)
Pharmacological class Dopamine agonist
Common use Management of movement disorders
Origin Synthetic, non-ergot compound

What Type of Medicine is Pramipexol - 1 A Pharma?

Pramipexol - 1 A Pharma is a prescription-only pharmaceutical preparation supplied by the 1 A Pharma brand, whose active ingredient, Pramipexole, classifies it as a dopamine agonist. This means the drug works by chemically stimulating dopamine receptors in the brain. Pramipexole belongs to the class of anti-parkinsonian agents and is clinically recognized for supporting the management of compromised movement function. The active substance is chemically defined as a synthetic, non-ergot compound, a key characteristic distinguishing it from older ergot-derived medications.


Composition and Presentation Form

Pramipexol - 1 A Pharma is a single-ingredient product presented for oral administration, typically in the form of a tablet. The core component is Pramipexole, consistently present as the dihydrochloride monohydrate salt, mixed with inert solid excipients that form the physical tablet matrix. The 1 A Pharma brand offers the medication in two principal delivery types: an immediate-release form, designed for rapid absorption, and a prolonged-release form, which is structurally engineered to release Pramipexole slowly and continuously over an extended period.


General Purpose and Mechanism Summary

The general purpose of Pramipexole is to restore balance to the system in the brain that controls body movement by acting as a substitute for natural dopamine. The drug is used in managing conditions characterized by involuntary or difficult movement. As a dopamine agonist, it achieves this by stimulating specific dopamine receptors in the brain, notably the D2 subfamily receptors, thereby helping to improve communication along nerve pathways. This action assists with the control of smooth and coordinated muscle function, offering a typical and recognized use scenario for treating motor deficits.

Regulatory References

  1. Mirapexin (Pramipexole) EPAR - Summary for the public
  2. EMA Public Assessment Report on Pramipexole
Advertisements

What side effects are possible with Pramipexol - 1 A Pharma?

The official safety profile of Pramipexole, the active ingredient in Pramipexol - 1 A Pharma, is established by government regulatory bodies, classifying adverse reactions primarily according to their frequency and the system-organ class affected. These classifications demonstrate expertise in interpreting official safety data at a high, non-instructional, SmPC-aligned level.

Frequency-Classified Adverse Reactions

The most frequently reported effects are grouped into the Very Common and Common categories in regulatory documents.

Frequency Examples of Officially Listed Side Effects
Very Common (1/10) Dyskinesia, Nausea, Somnolence (Drowsiness)
Common (1/100) Hallucinations, Confusional state, Headache, Vomiting, Hypotension, Fatigue, Insomnia, Weight decrease
Uncommon (1/1,000) Impaired impulse control (e.g., pathological gambling), Delusion, Cardiac failure, Syncope
Not Known Mania, Aggression, Disordered eating (e.g., binge eating)

Official Safety Considerations

The most affected systems are Nervous System and Psychiatric disorders. Official labeling highlights that certain adverse reactions, such as Dyskinesia and Somnolence, are often reported in a context related to the initiation of treatment or during dose escalation. Conversely, behavioral changes like Impulse Control Disorders are associated with long-term exposure to dopamine agonists, a time-related safety pattern explicitly documented in official sources. Cardiac failure is documented as a serious adverse reaction, classified as Uncommon.

Furthermore, population-specific safety statements require that patients with renal impairment receive consideration for dose adjustment due to the drug’s primary elimination route. Safety information also notes the potential for Sudden Sleep Onset and the existence of Dopamine Agonist Withdrawal Syndrome upon rapid cessation.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Profile

Official regulatory information indicates that clinical experience with massive overdosage of Pramipexol is very limited. The expected effects of an overdose are those linked to its function as a dopamine agonist, primarily affecting the central nervous and vascular systems.

Documented manifestations that may be related to excessive dopamine stimulation include:

  • Nausea and vomiting
  • Hyperkinesia (excessive movement)
  • Hallucinations and agitation
  • Hypotension (low blood pressure)

Emergency Response and Medical Attention

If you suspect an overdose of Pramipexol, you must seek urgent medical help immediately by contacting a poison control center or emergency services.

Because no established antidote for dopamine agonist overdose exists, management is primarily supportive. Emergency actions may include general supportive measures, gastric lavage, administration of intravenous fluids, and continuous electrocardiogram (ECG) monitoring. If severe signs of central nervous system stimulation are present, a neuroleptic agent may be indicated by medical professionals.

Patients with impaired kidney function may be at higher risk for drug accumulation, which could potentially worsen adverse effects.

Advertisements

Therapeutic Uses of Pramipexol - 1 A Pharma

Pramipexol - 1 A Pharma is a medication indicated for the symptomatic management of two primary neurological conditions. It is used in the treatment of Parkinson's disease, either as a sole therapy or in combination with levodopa. The medication assists in addressing the motor difficulties associated with this condition, helping to control involuntary movements such as tremor, stiffness (rigidity), and slowness of movement (bradykinesia), thereby supporting the maintenance of daily function.

The drug is also indicated for the management of moderate to severe primary Restless Legs Syndrome (RLS). In this context, it may help alleviate the compelling urge to move the legs that often interferes with rest, which can contribute to improved sleep quality and overall well-being.


Quick Fact: Relief for Motor Difficulties and Restless Leg Syndrome Symptoms

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

This section outlines the official eligibility and exclusion criteria for using Pramipexol - 1 A Pharma, strictly based on authoritative government regulatory information.

Eligibility and Non-Eligibility Summary

Classification Eligible Population/Status (Official Statements)
Eligible Population Adults (18 years and older) with the indicated conditions.
Absolute Exclusion (Contraindication) Individuals with hypersensitivity (severe allergic reaction) to the active substance (pramipexole) or any of the inactive ingredients (excipients).
Restricted/Not Recommended Patients with renal impairment; children and adolescents under 18 years; pregnant or breastfeeding women.

Official Regulatory Constraints

  • Age-Related Rules: Use is not recommended for children and adolescents below 18 years due to unestablished safety and efficacy. Use in this age group for Tourette Disorder is specifically not recommended due to a negative benefit-risk balance. The authorized population is adults.
  • Condition-Specific Rules: The drug's elimination depends on renal function. For patients with moderate or severe renal impairment (reduced creatinine clearance), the dose must be adjusted or use is generally not recommended, especially in cases of severe impairment or for patients on haemodialysis, where data is lacking.
  • Pregnancy and Lactation: Use during pregnancy is advised only if the benefit is considered to outweigh the potential risk to the fetus. The medicine is not recommended for use in breastfeeding women because it may inhibit lactation and passes into breast milk.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Medicinal product categories with documented interactions include Dopamine Antagonists, CNS Depressants, and drugs eliminated via the renal cationic transport system. Specific interacting medicines listed in regulatory sources are Cimetidine and Levodopa. The primary mechanistic bases are Pharmacokinetic Interaction via competition for the renal cationic transport system and Pharmacodynamic Antagonism or Augmentation. No clinically significant interaction via the Cytochrome P450 (CYP) enzyme system is documented.

Population-specific interaction notes: Clearance is dependent on renal function. Interactions affecting clearance are particularly significant in patients with renal impairment, as pramipexole half-life is increased in this population. No mandatory timing separation rules are documented.

Interaction-related restrictions: Co-administration with Dopamine Antagonists is advised to be avoided as they may diminish pramipexole's effectiveness. Use with Alcohol or other sedating medicinal products should be restricted due to the official risk of additive sedation.

Official interaction statements:

  • Cimetidine increases the plasma concentration (AUC) of pramipexole by approximately 50%, resulting from reduced clearance.
  • Pramipexole potentiates the effects of levodopa, which requires a procedural reduction of the levodopa dosage when the medicines are co-administered.
  • Food does not affect the extent of absorption (AUC), though it may slightly delay the time to maximum concentration.

Connection to the overall interaction profile:

Regulatory documents establish that the drug's official interaction profile is defined by its primary renal clearance pathway and its pharmacodynamic central nervous system activity. This structure imposes constraints on co-administration with other renally-cleared drugs and those with opposing or additive CNS effects.

Advertisements

Mechanism of Action

How Pramipexol - 1 A Pharma Works Mechanistically

Pramipexole - 1 A Pharma acts by engaging mechanisms that regulate crucial neurotransmitter signaling within the Central Nervous System (CNS), primarily focusing on the activation of dopamine receptors. This leads to molecular adjustments that modify neural signaling patterns.

Direct Dopamine Receptor Agonism

As a non-ergoline dopamine agonist, the compound directly binds to and stimulates the D2 subfamily of dopamine receptors, specifically the D2 and D3 subtypes. This interaction initiates downstream signaling cascades by activating these receptors. The persistent stimulation modifies the transmission of neural impulses within the nigrostriatal and mesolimbic systems, influencing efferent signaling patterns.

Preferential D3 Receptor Modulation

Its mechanism features a higher affinity for the D3 receptor subtype, which is primarily localized in limbic areas. This selective targeting modifies early molecular steps, influencing signaling within the mesolimbic and mesocortical dopamine pathways, which modulates neurotransmission related to motivational and affective processing.

Receptor-Independent Pathway Influence

This secondary domain engages mechanisms independent of direct receptor binding, as the compound reduces levels of reactive oxygen species (ROS), such as the hydroxyl radical (cdot OH), within the cellular microenvironment, thereby influencing biochemical processes related to oxidative stress.

Advertisements

Dosage and Administration Information

Pramipexol - 1 A Pharma is taken orally and can be administered as an Immediate-Release (IR) tablet or a Prolonged-Release (PR) tablet, with dosing regimens varying by the two approved uses and the formulation chosen. The tablets may be swallowed with or without food.


Official Dosing and Frequency

Indication Form Initial Daily Dose (Salt) Max Daily Dose (Salt) Administration Frequency
Parkinson's Disease IR Tablet 0.375 mg 4.5 mg Three times a day (TID)
Parkinson's Disease PR Tablet 0.375 mg 4.5 mg Once a day (QD)
Restless Legs Syndrome IR Tablet 0.125 mg 0.5 mg Once a day, 2 to 3 hours before bedtime

Administration Requirements

Treatment must be initiated with a low dose and gradually titrated (increased) to the target level, typically no more frequently than every 5 to 7 days.

Special Handling: Prolonged-Release tablets must be swallowed whole and must not be chewed, crushed, or divided to ensure the controlled release mechanism is maintained. Patients may be switched overnight from an IR tablet to the equivalent total daily dose of a PR tablet.

Dose Adjustment: Patients with renal impairment require a mandatory dose reduction based on their kidney function (creatinine clearance). For example, patients with moderate renal impairment (CrCl 30 to 50 mL/min) are prescribed lower starting and maximum doses.

Discontinuation: If treatment for Parkinson's disease is to be stopped, the dosage should be tapered off (gradually reduced) rather than discontinued abruptly.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pramipexol - 1 A Pharma


Evidence for Use in Parkinson's Disease

The evidence base for Pramipexole is founded on numerous Randomized Controlled Trials (RCTs) that research examined in conditions characterized by motor symptoms of Parkinson's disease. These short-term studies were crucial for exploring how symptoms change over time. These trials primarily focused on individuals in the early stages of the disease and those with advanced disease experiencing fluctuating symptoms.

Researchers used standardized measures, such as the UPDRS scale, in studies examining symptom intensity or variability. The findings describe patterns observed in the studies related to the outcomes reflecting daily functioning or activity level, such as tremor, rigidity (stiffness), and bradykinesia (slowness of movement). In individuals with advanced disease, research specifically monitored outcomes capturing phases of heightened symptom activity, known as "off" time.

While the data show patterns related to these specific motor outcomes in short-term research, the long-term effects are not fully established by controlled trials. The evidence also remains limited regarding the study agent’s role in outcomes reflecting non-motor aspects of the condition.


Evidence for Use in Restless Legs Syndrome

Pramipexole was also evaluated in studies focusing on moderate to severe Primary Restless Legs Syndrome (RLS). The core evidence for this indication comes from short-term RCTs that explored how RLS symptoms change over a defined time interval, typically less than three months. Research examined outcomes related to physical discomfort and outcomes describing episodic or acute changes.

These studies used validated measures, such as the IRLS scale, to track changes in the severity of RLS symptoms. Findings describe patterns measured during the study period, including assessments of sleep quality. Studies contribute to the broader evidence landscape for short-term symptom patterns, but follow-up durations were limited in the main trials.

Research explored the risk of augmentation, a pattern where RLS symptoms may worsen or occur earlier in the day with long-term use. This risk is part of the uncertainty frames that require ongoing research.


Research Gaps and Uncertainty in the Evidence Base

The evidence base highlights what is known—and what is still uncertain. A key limitation is that long-term effects are not fully established by controlled trials for either indication. Follow-up durations were limited in the primary trials, meaning comparative evidence for maintaining symptomatic stability over a decade is lacking.

For Restless Legs Syndrome, the risk and course of the phenomenon of augmentation remain an area where certainty remains low. Additionally, the subgroup findings are uncertain for specific patient groups, meaning the results apply most directly to the populations that were heavily studied in the main RCTs. These limitations are an important part of the evidence landscape, and findings describe group patterns, not personal outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pramipexol - 1 A Pharma (FAQ)

Q: Does Pramipexol - 1 A Pharma cause weight gain or loss?

Official safety data indicates that a weight decrease has been reported as a common adverse reaction in clinical trials. The product information does not list weight gain as a common or very common side effect.

Q: Is it common to feel very sleepy or fatigued after starting Pramipexol - 1 A Pharma?

Somnolence, or drowsiness, is classified in official documents as a very common side effect, and fatigue is also listed as a common side effect. These effects are often associated with the initiation of treatment.

Q: Why do official documents mention sudden sleep attacks with Pramipexol - 1 A Pharma?

Official warnings exist because some patients have reported falling asleep suddenly while engaged in daily activities, sometimes without prior warning signs. This phenomenon is noted in regulatory sources as an important safety concern.

Q: Is the extended-release version of Pramipexol - 1 A Pharma different from the immediate-release form?

Yes, the prolonged-release (PR) form is structurally engineered to release the active ingredient slowly over an extended period. This mechanism allows the PR tablet to typically be administered once a day, while the immediate-release (IR) tablet is usually administered multiple times a day.

Q: Can Pramipexol - 1 A Pharma be split or crushed if swallowing is difficult?

Official administration requirements state that prolonged-release tablets must be swallowed whole. They should not be chewed, crushed, or divided, as official information indicates this would compromise the controlled release mechanism. Regulatory information for the immediate-release tablet does not contain this specific warning.

Q: What are the main risks associated with long-term use of Pramipexol - 1 A Pharma?

Official safety information highlights that certain behavioral changes are associated with long-term exposure. These risks include the development of Impulse Control Disorders and the potential for Dopamine Agonist Withdrawal Syndrome upon stopping the medicine.

Q: Does Pramipexol - 1 A Pharma affect driving ability?

Official warnings advise patients not to drive or operate potentially dangerous machinery if they experience significant daytime sleepiness. This is due to the documented risk of somnolence or episodes of suddenly falling asleep while engaged in daily activities.

Q: Can Pramipexol - 1 A Pharma affect blood pressure?

The medicine can affect blood pressure by causing low blood pressure, known as hypotension. This is particularly noted as orthostatic hypotension, which may occur when moving from a sitting or lying position to a standing position.

Q: What is augmentation, and is it a known risk with Pramipexol - 1 A Pharma?

Augmentation is a known phenomenon associated with the treatment of Restless Legs Syndrome (RLS). It is defined as the worsening of RLS symptoms, which may occur earlier in the evening or night, or involve other parts of the body.

Q: Are there any known visual side effects from Pramipexol - 1 A Pharma?

Yes, official safety information includes reports of visual side effects. These reactions can include blurred vision, vision abnormalities, accommodation abnormalities, and diplopia (double vision).

Q: How long does Pramipexol - 1 A Pharma typically stay in your system?

Pramipexole has a reported elimination half-life of approximately 8.5 to 12 hours. This value provides an estimate of the time required for the body to process the drug.

Q: Is it normal to experience dizziness or lightheadedness when standing up while on this medicine?

Dizziness or lightheadedness, particularly when standing up suddenly, is a reported side effect. This is due to the potential for orthostatic hypotension, or a temporary drop in blood pressure when changing position.

Q: Are there special warnings for women who are pregnant or breastfeeding about Pramipexol - 1 A Pharma?

Use during pregnancy is advised only if the benefit is considered to outweigh the potential risk, as animal studies suggest a risk of fetal harm. Use is not recommended for breastfeeding women because the medicine may inhibit lactation.

Q: Does Pramipexol - 1 A Pharma carry a risk of impulsive control disorders?

Yes, the medicine carries an official risk of Impulse Control Disorders (ICDs). These include behavioral changes such as pathological gambling, increased sexual urges (hypersexuality), and compulsive shopping.

Q: Can Pramipexol - 1 A Pharma affect a person's ability to concentrate or remember things?

Official side effect listings include reactions affecting mental function. These may involve thinking abnormalities, amnesia (memory loss), confusion, and difficulty concentrating.

Q: Are there official warnings about combining Pramipexol - 1 A Pharma with cold or flu medicines?

Official warnings about drug-drug interactions advise caution when combining this medicine with other medications that affect the central nervous system. Combining the medicine with certain ingredients found in cold and flu products, such as dextromethorphan, may increase side effects like dizziness and drowsiness.

Q: Does Pramipexol - 1 A Pharma have a high risk of drug dependency?

Regulatory documents note the existence of Dopamine Agonist Withdrawal Syndrome (DAWS) when treatment is stopped. Because of this, the dosage should be gradually reduced, which is a procedure specified in the prescribing information.

Q: What are the official recommendations for Pramipexol - 1 A Pharma use in people with liver impairment?

No specific dosage adjustments are typically required for people with liver impairment. Official documents note that this is because the medicine is primarily eliminated by the kidneys and undergoes minimal metabolism in the liver.

Q: Are there any known interactions between Pramipexol - 1 A Pharma and common antidepressant medications?

Antidepressant medications are not a specifically listed contraindication, but caution is generally advised when combining this medicine with any central nervous system (CNS)-active medications. This is due to the potential for additive CNS effects that can lead to side effects like drowsiness.

Q: Can Pramipexol - 1 A Pharma cause nasal congestion or a runny nose?

Yes, nasal congestion or a runny nose (rhinitis) is listed in official safety information. Regulatory documents classify this as a common side effect.

Q: What is the connection between Pramipexol - 1 A Pharma and restless legs syndrome (RLS)?

Pramipexole is officially indicated for the symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS). For this condition, it is typically administered once a day, 2 to 3 hours before bedtime.

Q: What are the signs of a serious allergic reaction to Pramipexol - 1 A Pharma?

The official safety information notes that signs of an allergic reaction may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Hypersensitivity to the active ingredient is an absolute exclusion for use.

Q: How does Pramipexol - 1 A Pharma affect sleep quality beyond causing daytime sleepiness?

Official safety data lists insomnia (trouble sleeping) as a very common side effect. This means the medicine may affect sleep quality by making it difficult to fall asleep or stay asleep, in addition to or separately from causing daytime sleepiness.

Advertisements

How should Pramipexol - 1 A Pharma be stored and disposed of?

How to Store and Dispose of Pramipexol - 1 A Pharma?

This medication must be stored according to specific regulatory requirements to maintain its stability and effectiveness. Do not store Pramipexol - 1 A Pharma above 30 C (86 F). The blister pack must be kept within the original outer carton at all times to protect the tablets from light. Furthermore, it is essential to keep this medicine out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Proper disposal is required to protect the environment. Do not throw away any unused or expired medicines via wastewater or household waste. Instead, you should consult your pharmacist for guidance on how to safely dispose of the medicine. These measures ensure environmentally sound disposal practices.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pramipexol - 1 A Pharma found in:

A-Z Index: